IVW vs XBI
iShares S&P 500 Growth ETF vs SPDR S&P Biotech ETF
- • IVW has the lower expense ratio at 0.18% vs 0.35% for XBI.
Side-by-side metrics
| Metric | IVW | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.18% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.36% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $74.97B | $10.73B |
YTD return | 10.73% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.20 | 1.10 |
P/E ratio | 30.42 | — |
Last price | $137.74 | $164.01 |
Inception | — | — |
Issuer | iShares | State Street |
IVW top holdings
| NVDA | NVIDIA Corp | 13.65% |
| MSFT | Microsoft Corp | 7.80% |
| AAPL | Apple Inc | 5.98% |
| GOOGL | Alphabet Inc Class A | 5.90% |
| AVGO | Broadcom Inc | 5.04% |
| GOOG | Alphabet Inc Class C | 4.70% |
| MU | Micron Technology Inc | 3.67% |
| META | Meta Platforms Inc Class A | 3.48% |
| AMZN | Amazon.com Inc | 3.48% |
| LLY | Eli Lilly and Co | 2.67% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About IVW
IVW (iShares S&P 500 Growth ETF) is S&P 500 growth subset. Managed by iShares, the fund carries $75.0B in assets under management, an expense ratio of 0.18%, a dividend yield of 0.36%. Its largest holding is NVIDIA Corp (NVDA), which represents 13.6% of the portfolio. Real Estate is the fund's largest sector exposure at 0.6%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.